BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yuan J, Yu J, Huang Y, He Z, Luo J, Wu Y, Zheng Y, Wu J, Zhu X, Wang H, Li M. Antibiotic fidaxomicin is an RdRp inhibitor as a potential new therapeutic agent against Zika virus. BMC Med 2020;18:204. [PMID: 32731873 DOI: 10.1186/s12916-020-01663-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Abdulaziz L, Elhadi E, Abdallah EA, Alnoor FA, Yousef BA. Antiviral Activity of Approved Antibacterial, Antifungal, Antiprotozoal and Anthelmintic Drugs: Chances for Drug Repurposing for Antiviral Drug Discovery. JEP 2022;Volume 14:97-115. [DOI: 10.2147/jep.s346006] [Reference Citation Analysis]
2 Kirsch SH, Haeckl FPJ, Müller R. Beyond the approved: target sites and inhibitors of bacterial RNA polymerase from bacteria and fungi. Nat Prod Rep 2022. [PMID: 35507039 DOI: 10.1039/d1np00067e] [Reference Citation Analysis]
3 Patil SM, Martiz RM, Ramu R, Shirahatti PS, Prakash A, Chandra S J, Ranganatha VL. In silico identification of novel benzophenone-coumarin derivatives as SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) inhibitors. J Biomol Struct Dyn 2021;:1-17. [PMID: 34632942 DOI: 10.1080/07391102.2021.1978322] [Reference Citation Analysis]
4 Anand J, Ghildiyal T, Madhwal A, Bhatt R, Verma D, Rai N. Computational guided approach for drug repurposing against SARS-CoV-2. Future Virology 2021;16:211-43. [DOI: 10.2217/fvl-2020-0403] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]